The Effect of Palmitoylethanolamide on Pain Intensity, Central and Peripheral Sensitization, and Pain Modulation in Healthy Volunteers—A Randomized, Double-Blinded, Placebo-Controlled Crossover Trial
Randomised controlled trialHumans
- Design
- Randomised controlled trial
- Subjects
- 14 healthy volunteers, in a crossover design
- Dose used in the study
- 400 mg three times a day, against placebo
- Duration
- 4 weeks on each
- What was measured
- Responses to a standard laboratory pain model using repeated heat, plus cold, pressure and heat pain tolerance, wind-up and allodynia, and conditioned pain modulation
What the authors reported
The authors reported that repeated heat pain fell, cold and heat pain tolerance rose, pressure tolerance and conditioned pain modulation increased, and wind-up and allodynia decreased after palmitoylethanolamide. They concluded that it acts on both peripheral and central pain mechanisms.
Limits of this study
14 healthy people and experimental pain, not patients with a pain condition. A mechanism study in humans, from the same group that later published the 2023 meta-analysis. It was funded by the City of Graz.
Source
Entry checked against the abstract and citation held by Crossref, the DOI registry on 2026-09-21. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.